Helmerich & Payne, Inc. To Participate in Conferences in March 2025
TULSA, Okla., March 17, 2025--(BUSINESS WIRE)--Helmerich & Payne, Inc. (NYSE: HP) today announced that John Lindsay, President and Chief Executive Officer; Kevin Vann, Senior Vice President and Chief Financial Officer; and Dave Wilson, Vice President of Investor Relations plan to participate in the following investor conferences during the month of March 2025. Participation by the management team will vary by event.
The Piper Sandler 25th Annual Energy Conference on Tuesday and Wednesday, March 18-19, 2025; Lindsay will participate in a panel discussion on behalf of the Company on Wednesday, March 19, 2025 at 10:45 a.m. U.S. PT.
The NYSE Energy & Utilities Virtual Investor Access Day on Thursday, March 20, 2025.
Market Update: Subsequent to H&P's first fiscal quarter of 2025 earnings release on February 5, 2025, the Company received notices of contract suspensions for an additional two rigs from the legacy KCA Deutag rig fleet operating in Saudi Arabia. This brings the Company's total rig suspensions in country to 14 rigs.
President and CEO John Lindsay commented, "While these incremental suspensions are disappointing, we do not expect them to have an incremental adverse material impact on the Company's financial position. As we have mentioned previously, we remain positive on the long-term strategic prospects of having a large-scale drilling presence in the region and are actively pursuing the cost synergies we discussed on the first fiscal quarter earnings conference call."
About Helmerich & Payne, Inc.
Founded in 1920, Helmerich & Payne, Inc. is committed to delivering industry leading drilling productivity and reliability. H&P operates with the highest level of integrity, safety and innovation to deliver superior results for our customers and returns for shareholders. Through its subsidiaries, the Company designs, fabricates and operates high-performance drilling rigs in conventional and unconventional plays around the world. H&P also develops and implements advanced automation, directional drilling and survey management technologies. For more information, visit hpinc.com.
Forward Looking Statements
This release includes "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, and such statements are based on current expectations and assumptions that are subject to risks and uncertainties. All statements other than statements of historical facts included in this release, including, without limitation, statements regarding the anticipated benefits (including synergies and cash flow and free cash flow accretion) of the acquisition and integration of KCA Deutag, the anticipated impact of the acquisition of KCA Deutag on the Company's business and future financial and operating results, the anticipated timing of expected synergies and returns from the acquisition of KCA Deutag, the anticipated number of and impact of suspended rigs related to the Acquisition, the timing and terms of recommencement of suspended rigs related to the Acquisition, the Company's business strategy, future financial position, operations outlook, future cash flow, future use of generated cash flow, dividend amounts and timing, amounts of any future dividends, investments, active rig count projections, projected costs and plans, objectives of management for future operations, contract terms, financing and funding, capex spending and budgets, outlook for domestic and international markets, future commodity prices, future customer activity and relationships and the expected impact of the integration of KCA Deutag are forward-looking statements. For information regarding risks and uncertainties associated with the Company's business, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections and other disclosures in the Company's SEC filings, including but not limited to its annual report on Form 10‑K and quarterly reports on Form 10‑Q. As a result of these factors, Helmerich & Payne, Inc.'s actual results may differ materially from those indicated or implied by such forward-looking statements. Investors are cautioned not to put undue reliance on such statements. We undertake no duty to publicly update or revise any forward-looking statements, whether as a result of new information, changes in internal estimates, expectations or otherwise, except as required under applicable securities laws.
Helmerich & Payne uses its website as a channel of distribution for material company information. Such information is routinely posted and accessible on its Investor Relations website at hpinc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317555170/en/
Contacts
IR Contact: Dave Wilson, Vice President of Investor Relations918-588-5190investor.relations@hpinc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Palantir's H-1B Hiring Sparks Fears Over Sensitive U.S. Data Access
Palantir Technologies, the surveillance giant under growing scrutiny for its ties to the Trump administration, employs scores of foreign workers even as it helps compile vast amounts of sensitive data on Americans. Palantir sponsored 78 foreign workers in 2024 — the most recent year for which data is available — and has sponsored 263 workers under the program since 2020, The H-1B Salary Database indicates that about half of these roles are for AI and software engineering positions, placing foreign nationals in critical technical roles at a company now reportedly embedded in the core operations of U.S. federal agencies. Nationals from India and China receive the most H-1B visas of any country's workers. USCIS data reveals that during fiscal year 2023, 72% of H-1B visas were issued to Indians, while 12% went to the Chinese. The database disclosures stand in stark contrast to recent revelations from The New York Times, which reported on May 30 that Palantir has become the centerpiece of an ambitious effort by the Trump administration to centralize federal data on American citizens. The reporting detailed how Palantir's Foundry platform is being adopted across agencies, including the Department of Homeland Security (DHS), Health and Human Services, and the Internal Revenue Service (IRS), enabling the administration to merge disparate databases that contain financial, medical, and immigration records. The Times reported that Palantir, co-founded by Peter Thiel and led by CEO Alex Karp, received more than $113 million in federal contracts under the Trump administration, not including a new $795 million Department of Defense award. Former employees and privacy advocates voiced concern that the company — already entwined with Immigration and Customs Enforcement (ICE) and the Pentagon — is facilitating the construction of what critics describe as a potential 'national citizen database.' The concerns are compounded by the company's international footprint and foreign staffing. Palantir lists between 1,000 and 5,000 employees on LinkedIn, with most external estimates placing its global headcount at just under 4,000. The company maintains a presence on every inhabited continent — including operations and staff in Asia and Europe, according to LeadIQ. A recent Business Insider Africa report also confirmed that Palantir provides artificial intelligence tools to foreign militaries, including those of Israel and Ukraine. The firm held its first 2025 board meeting in Tel Aviv and has partnered with the Israeli Ministry of Defense to support ongoing war efforts. The optics of such international entanglements have not gone unnoticed among former staff. In a letter obtained by NPR and published May 5, thirteen former Palantir employees condemned the company's expanding work with the Trump administration, particularly its $30 million deal with ICE to develop a system capable of tracking migrant movement in near real-time. 'Early Palantirians understood the ethical weight of building these technologies… These principles have now been violated and are rapidly being dismantled at Palantir Technologies,' the ex-employees wrote. The former employees also warned that the software they helped build could now be used for surveillance targeting immigrant families, journalists, and political dissenters. The New York Times further detailed internal dissent among employees disturbed by the firm's proximity to Trump's political agenda. Some engineers reportedly raised red flags about inadequate security practices among Department of Government Efficiency (DOGE) staff — a Trump-aligned task force spearheading the data initiative, many of whom previously worked at Palantir or companies funded by Thiel. Despite public concerns, Palantir has emphasized that it acts only as a data processor. In a 2020 blog post, the company The White House declined to comment for the Times story but pointed to President Trump's executive order mandating that federal data silos be eliminated in favor of cross-agency access. Supporters argue the plan increases government efficiency and saves taxpayer money. However, critics — including civil liberties lawyers — have warned that concentrating this data creates new risks of abuse. Mario Trujillo of the Electronic Frontier Foundation told the Times, 'If people can't trust that the data they are giving the government will be protected, it will lead to a crisis of trust.' The Dallas Express contacted Palantir to ask whether H-1B workers are processing sensitive American data; a company spokesman did not return a comment by the time of publication.
Business Upturn
2 hours ago
- Business Upturn
URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)
NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting Investors have until July 28, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased UroGen securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Cockrell v. UroGen Pharma Ltd., et al. , No. 3:25-cv-06088. Why was UroGen Sued for Securities Fraud? UroGen develops treatments for specialty cancers. The Company's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. One of the Phase 3 trials for UGN-102 is named ENVISION. As alleged, UroGen stated that the ENVISION trial met its primary endpoint and that UroGen had reached 'agreement with the FDA' that the ENVISION trial would support an NDA submission. In truth, the FDA had previously expressed significant concerns to UroGen regarding the ENVISION trial, which lacked a concurrent control arm. The Stock Declines as the Truth is Revealed On May 16, 2025, the FDA published a briefing document stating that it doubted whether the submitted data was sufficient to conclude that UGN-102 was effective. FDA stated that because 'ENVISION lacked a concurrent control arm,' the primary endpoints were 'difficult to interpret' and that UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock declined $2.54 per share, or nearly 26%, from a closing price of $9.85 per share on May 15, 2025, to $7.31 per share on May 16, 2025. Then, on May 21, 2025, the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk profile of UGN-102 was not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock declined $3.37 per share, or nearly 45%, from a closing price of $7.54 per share on May 20, 2025, to $4.17 per share on May 21, 2025. Click here if you suffered losses: What Can You Do? If you invested in UroGen you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
New York Post
3 hours ago
- New York Post
Last-minute tax filer? This H&R Block deal can help
Discover startups, services, products and more from our partner StackCommerce. New York Post edits this content, and may be compensated and/or receive an affiliate commission if you buy through our links. TL;DR: File your taxes affordably with the H&R Block Deluxe + State 2024 Tax Software for Mac and Windows, on sale now for just $39.99 (reg. $59.99) while codes last. Are you ready to finally tackle your taxes? If you got an extension and still need to file, you're in luck. You can now score a great deal on H&R Block Deluxe + State 2024 Tax Software (compatible with Windows and Mac) for just $39.99 (reg. $59.99) — which is less than what you'd normally pay just to file your federal taxes — while supplies last. Most tax software charges upwards of $100 to file your state and federal taxes, but this deal on H&R Block Deluxe and State 2024 Tax Software lets you file both for $40. That's a better deal than TurboTax and offers similar features. And if you previously filed with a competitor, don't worry. H&R Block's software makes it easy to import last year's filing from other platforms. New York Post If you're a first-time filer, rest easy knowing H&R Block takes you through the process step-by-step. It's great for freelancers, investors, and retirees alike, and helps ensure you get the best tax refund possible by checking over 350 credits and deductions that will help maximize your return. It can help with confusing income sources, like stocks, investments, and retirement accounts, and you can use the built-in income reporting tools and get the guidance you need. If you have questions, the help center has searchable articles ready to assist you. You'll also have access to audit support to give you peace of mind after filing. Finish your taxes with the H&R Block Deluxe + State 2024 Tax Software for Mac and Windows, on sale now for just $39.99 (reg. $59.99). StackSocial prices subject to change.
